Dancann Pharma A/S

DANCAN

DK0061410487

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
0.07 ^DKK	-12.50%		0.00%	+133.33%

Mar. 29	Dancann Pharma Plans Up to DKK19 Million Rights Issue	MT
Feb. 28	DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge	MT

DanCann Pharma A/S Appoints Sarah Mai Lykke-Kjeldsen as New Chief Operating Officer, Effective 1 April 2022

March 28, 2022 at 08:40 am EDT

DanCann Pharma A/S announced that the company has appointed Sarah Mai Lykke-Kjeldsen as new Chief Operating Officer. Sarah Mai Lykke-Kjeldsen will join DanCann Pharma on 1 April 2022.

Latest news about Dancann Pharma A/S

Dancann Pharma Plans Up to DKK19 Million Rights Issue	Mar. 29	MT
DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge	Feb. 28	MT
Dancann Pharma A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Dancann Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Dancann Pharma A/S Provides Revenue Guidance for the Financial Year 2025	Dec. 20	CI
Dancann Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 30	CI
DanCann Pharma Issues New Shares For Debt Conversion	Nov. 23	MT
DanCann Pharma Issues New Shares Following Debt Conversion	23-10-04	MT
DanCann Pharma Issues New Shares Upon Debt Conversion	23-09-26	MT
Dancann Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
DanCann Mulls Sale of Production Facility Amid Shift in Business Strategy; Shares Plunge 13%	23-08-31	MT
DanCann Pharma Issues New Shares Upon Debt Conversion	23-08-21	MT
Dancann Pharma Lands DKK7 Million Debt Financing From Nordic Growth Fund; Shares Up 11%	23-07-18	MT
Dancann Pharma A/S' Pre-Validation Batches Meets European Standards, Paving the Path for Final Product Approval	23-06-01	CI
Dancann Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Dancann Pharma A/S Appoints Louise Bertelsen Forman as A New Additional Board Member	23-05-30	CI
Dancann Pharma Expects Final Danish Approval for Biotech Pharm1 Facility by End-summer	23-05-26	MT
Dancann Pharma in Advanced Talks for DKK12 Million Convertible Loan Deal	23-05-26	MT
Dancann Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-12	CI
Dancann Pharma A/S Auditor Raises 'Going Concern' Doubt	23-05-11	CI
DanCann Pharma to Distribute Prescription Cannabinoid-based Medications in Scandinavian Markets	23-05-09	MT
Dancann Pharma A/S Provides Positive Insight on Progress of Cannabis Bulk Product Approval	23-03-14	CI
Dancann Pharma A/S and Canngros Aps Open Office in Odense	23-02-23	CI
DanCann Pharma Hires New CFO	23-01-04	MT
DanCann Pharma A/S Appoints Peter Søndergaard as CFO	23-01-04	CI

Dancann Pharma A/S is a Denmark-based pharmaceutical biotechnology company powered by cannabinoids. The Company is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma manufactures and distributes prescription drugs (Rx drugs) and over-the-counter drugs (OTCs), mainly focused on pain patients with alternative needs.

Sector

Biotechnology & Medical Research

Calendar

2024-05-28 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DANCANN PHARMA A/S	+133.33%	1.7M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	114B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
BIONTECH SE	-11.90%	22.41B
ARGENX SE	+0.32%	22.28B
GENMAB A/S	-5.48%	19.07B
WUXI APPTEC CO., LTD.	-37.36%	18B
BEIGENE, LTD.	-5.17%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.28B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.55B

Bio Therapeutic Drugs